Becton Dickinson (NYSE:BDX) said today that it inked a research collaboration supported by the Juvenile Diabetes Research Foundation to develop an extended-wear insulin delivery device.
The collaboration is a 2-year funding commitment from JDRF to extend the lifetime of insulin infusion-delivery devices. Insulin infusion sets are cleared by the FDA for up to 3 days of use. JDRF will support Franklin Lakes, N.J.-based BD in addressing the mechanical-material and biological issues that contribute to the limited lifetime and design devices that enable infusion sets to be effective for an extended period of time.
Get the full story at our sister site, Drug Delivery Business News.